Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma
暂无分享,去创建一个
R. Fisher | S. Fox | B. Solomon | L. Peters | G. McArthur | D. Rischin | Kelly Waldeck | R. Young | J. Corry | A. Lim | R. J. Young
[1] André Raspaud,et al. On backbone coloring of graphs , 2012, J. Comb. Optim..
[2] K. Ang,et al. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. , 2011, International journal of radiation oncology, biology, physics.
[3] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[4] R. Fisher,et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Thorstad,et al. p16 Positive Oropharyngeal Squamous Cell Carcinoma:An Entity With a Favorable Prognosis Regardless of Tumor HPV Status , 2010, The American journal of surgical pathology.
[6] Gypsyamber D'Souza,et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. , 2010, The Lancet. Oncology.
[7] Jonathan R. Clark,et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. , 2010, European journal of cancer.
[8] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[9] S. Lippman,et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) , 2010, Head & neck oncology.
[10] R. Fisher,et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Meyer,et al. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. , 2010, Oral oncology.
[12] L. Terracciano,et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? , 2009, International journal of cancer.
[13] S. Fox,et al. Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial , 2010 .
[14] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[15] C. R. Leemans,et al. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. , 2009, European journal of cancer.
[16] Christine H Chung,et al. Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications , 2009, Clinical Cancer Research.
[17] F. Cappuzzo,et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer , 2009, Journal of Clinical Pathology.
[18] Martin Görner,et al. HPV & head and neck cancer: a descriptive update , 2009, Head & neck oncology.
[19] Jonathan R. Clark,et al. Prognostic Significance of Vascular Endothelial Growth Factor in Squamous Cell Carcinomas of the Tonsil in Relation to Human Papillomavirus Status and Epidermal Growth Factor Receptor , 2009, Annals of Surgical Oncology.
[20] T. Ried,et al. EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. , 2009, European journal of cancer.
[21] Albert C. Koong,et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. , 2009, International journal of radiation oncology, biology, physics.
[22] A. Russo,et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] L. Terracciano,et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. , 2008, Human pathology.
[24] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[25] C. Tsien,et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] W. Westra,et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.
[27] Jeremy MG Taylor,et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. , 2007, International journal of radiation oncology, biology, physics.
[28] Diane D. Liu,et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] H. Dienes,et al. Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer , 2007, International journal of cancer.
[30] E. Choi,et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c‐myc during tumor formation , 2007, International journal of cancer.
[31] M. Pierotti,et al. Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.
[32] Christine H Chung,et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Grandis,et al. Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Kodet,et al. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. , 2005, Neoplasma.
[35] R. Fisher,et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[37] R. Fisher,et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[39] R. Day,et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. , 1998, Journal of the National Cancer Institute.